BioSpace News Archive

Impel NeuroPharma (NASDAQ: IMPL), today announced it will host a live webcast on Thursday, March 24, 2022, at 8:30 a.m. ET to report its fourth quarter and full year 2021 financial results and provide a business update.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the fourth quarter and fiscal year ended December 31, 2021.

Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021.

Pressure BioSciences, Inc., a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, updated stakeholders on the Company’s key 2022 goals.

Agilex Biolabs Pty Ltd has unveiled its new building with a ribbon cutting ceremony by The Honourable Stephen Patterson MP Minister for Trade and Investment at 12:30pm on Thursday 17 February 2022 at 31 Dalgleish street Thebarton South Australia 5031.

The innate as well as adaptive immune response both has critical roles to fight against cancer. However, studies have shown that most effective tumor killing occurs when these work mutually.

Today, Health Canada authorized the use of the Moderna Spikevax (50 mcg) COVID-19 vaccine in children 6 to 11 years of age.

Paradigm Biopharmaceuticals (ASX: PAR) is announcing today the official launch of their U.S. clinical trial program with an estimated 56 planned clinical trial locations nationwide for the conduct of the pivotal phase 3 trial to support registration of Pentosan Polysulfate Sodium (PPS) for osteoarthritis (OA) of the knee.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, the European Organisation for Research and Treatment of Cancer (EORTC) and the European Thoracic Oncology Platform (ETOP) today announced results from the pivotal Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS.

Over the years, society has changed and thus, the environment. People are now more open to accepting assisted reproductive technology.